HIGHLIGHTS
- who: Yongfeng Yu and collaborators from the Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University have published the Article: Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison, in the Journal: (JOURNAL)
- what: The results of the analysis showed that in the first-line treatment of patients with ALK-positive NSCLC, brigatinib had better efficacy than crizotinib and ceritinib, and there was no significant difference in terms of PFS, OS, and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.